ATM kinase sustains HER2 tumorigenicity in breast cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Stagni, Venturina ^a,b   Manni, Isabella ^c   Oropallo, Veronica ^a,b   Mottolese, Marcella ^c   Di Benedetto, Anna ^c   Piaggio, Giulia ^c   Falcioni, Rita ^c   Giaccari, Danilo ^a,b   Di Carlo, Selene ^c   Sperati, Francesca ^c   Cencioni, Maria Teresa ^a   Barilà, Daniela ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; ATM PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN;

CANCER; ENZYME ACTIVITY; GENE EXPRESSION; PROTEIN; SIGNALING; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; UBIQUITINATION; ADULT; AGED; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CARCINOGENESIS; CARCINOMA; CASE CONTROL STUDY; FEMALE; GENETICS; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; TRANSGENIC MOUSE; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; MCF-7 CELLS; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84928041749     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7886     Document Type: Article

References (49)

1. Shiloh, Y. & Ziv, Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197-210 (2013).
2. Lavin, M. F., Gueven, N., Bottle, S. & Gatti, R. A. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br. Med. Bull. 81-82, 129-147 (2007).
3. Matei, I. R., Guidos, C. J. & Danska, J. S. ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: The DSB connection. Immunol. Rev. 209, 142-158 (2006).
4. Gumy-Pause, F., Wacker, P. & Sappino, A. P. ATM gene and lymphoid malignancies. Leukemia 18, 238-242 (2004).
5. Boultwood, J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J. Clin. Pathol. 54, 512-516 (2001).
6. Swift, M., Reitnauer, P. J., Morrell, D. & Chase, C. L. Breast and other cancers in families with ataxia telangiectasia. N. Engl. J. Med. 316, 1289-1294 (1987).
7. Lavin, M. F. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 9, 759-769 (2008).
8. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97, 813-822 (2005).
9. Stredrick, D. L. et al. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Hum. Mutat. 27, 538-544 (2006).
10. Goldgar, D. E. et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 13, R73 (2011).
11. Renwick, A. et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873-875 (2006).
12. Xu, Y. & Baltimore, D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10, 2401-2410 (1996).
13. Yang, D.-Q. & Kastan, M. B. Partecipation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat. Cell Biol. 2, 893-898 (2000).
14. Golding, S. E. et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 10, 2894-2902 (2009).
15. De Bacco, F. et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl Cancer Inst. 103, 645-661 (2011).
16. Halaby, M. J., Hibma, J. C., He, J. & Yang, D. Q. ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal. 20, 1555-1563 (2008).
17. Viniegra, J. G. et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem. 280, 4029-4036 (2005).
18. Cam, H., Easton, J., High, A. & Houghton, P. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1a. Mol. Cell 40, 509-520 (2010).
19. Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T. & Kubota, Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat. Med. 18, 1208-1216 (2012).
20. Valentin-Vega, Y. A. et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood 119, 1490-1500 (2012).
21. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
22. Baselga, J. Treatment of HER2-overexpressing breast cancer. Ann. Oncol. 21 Suppl 7, vii36-vii40 (2010).
23. Citri, A. & Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505-516 (2006).
24. Moasser, M. M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487 (2007).
25. Di Fiore, P. P. et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178-182 (1987).
26. Hudziak, R. M., Schlessinger, J. & Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl Acad. Sci. USA 84, 7159-7163 (1987).
27. Reddy, J. P. et al. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl Acad. Sci. USA 107, 3728-3733 (2010).
28. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
29. Bartek, J., Bartkova, J. & Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773-7779 (2007).
30. Haenssen, K. K. et al. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J. Cell Sci. 123, 1373-1382 (2010).
31. Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589-596 (1998).
32. Citri, A., Kochupurakkal, B. S. & Yarden, Y. The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3, 51-60 (2004).
33. Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65-72 (2002).
34. Minami, T. et al. Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. Sci. Rep. 3, 2669 (2013).
35. Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W. & Bissell, M. J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 122, 35-43 (2010).
36. Shou, J. et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004).
37. Massarweh, S. et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68, 826-833 (2008).
38. Larsson, L. G. & Henriksson, M. A. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp. Cell Res. 316, 1429-1437 (2010).
39. Bernardi, R. & Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8, 1006-1016 (2007).
40. Carracedo, A. et al. A metabolic prosurvival role for PML in breast cancer. J. Clin. Invest. 122, 3088-3100 (2012).
41. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166 (2007).
42. Biton, S. et al. Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J. Biol. Chem. 281, 17482-17491 (2006).
43. Mongiardi, P. et al. Oxygen sensing is impaired in ATM defective cells. Cell Cycle 10, 4311-4320 (2011).
44. Biton, S. et al. ATM-mediated response to DNA double strand breaks in human neurons derived from stem cells. DNA Repair (Amst) 6, 128-134 (2007).
45. Corso, S. et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27, 684-693 (2008).
46. Di Modugno, F. et al. The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS ONE 5, e15852 (2010).
47. Stagni, V. et al. ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 111, 829-837 (2008).
48. Furlan, A. et al. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ. 18, 1608-1616 (2011).
49. Tavassoli, F. A. & Devilee, P. (eds). Tumours of the breast and female genital organs (IARC Press, 2003).